Antibody Discovery and Characterization

IPA provides services to characterize valuable monoclonal antibodies. Specificity testing in various assays can be complemented with internalization, affinity ranking of antibody panels, and epitope binning, using BLI-based platforms. This also includes highly purified, well-characterized, low endotoxin, or labeled antibodies for various applications.

From decades of experience, the B cell Select platform allows for the interrogation of a great diversity of an animal’s antibody repertoire. Antibodies can be developed from any species (including human) or tissue, can explore the entire antibody repertoire, and identify antibodies for any possibilities in an animal’s immune repertoire including any protein class, complex therapeutic targets, post-translational modifications, and small molecules. The B cell Select technology enables the interrogation of 10 million immune cells to generate native, monoclonal antibodies from immunized animals that specifically target an antigen and allow for the rapid selection of top candidates, increasing the success rate of an antibody discovery program. The platform also harnesses the power of the immune system to generate natural pairing of the antibodies produced by selected B cells. The rabbit B cell Select platform boasts a >98% success rate in therapeutics, anti-drug and anti-id, and diagnostic antibody discovery.

IPA offers rabbit and chicken monoclonal antibody development. Proprietary technology from IPA allows for the screening of the immune repertoire of the animal, creating the power to select the desired antibody directly from the B cells using our B cell Select or phage display, antibody discovery platforms.

IPA uses proprietary, semi-solid media to grow mouse and rat hybridomas, post-fusion. This special media allows for the support and picking of single cell colonies immediately after the fusion and (hybridomas are essentially monoclonal from the start). No serial dilution (limiting dilution) cloning is required and all hybridomas that grow from the fusion can be tested for specific antibodies, within two weeks post-fusion. The quick detection of target-specific clones allows for immediate subcloning and cryopreservation of valuable cultures.

DeepDisplay technology utilizing a combination of any transgenic animal platform and custom IPA phage display antibody selection.

Our phage display approach is based on building custom immune libraries from multiple species, including transgenic animals, or the selection of antigen-specific recombinant antibody fragments from our proprietary, pre-made human or llama phage libraries. Our libraries have been made from human patient and naïve (scFv) repertoires, as well as from naïve llama (VHH) repertoires. DeepDisplay custom immune libraries are prepared from blood, spleen, lymph nodes, and bone marrow of immunized animals or humans and capture the entire immune repertoire for panning, rescue, and identification of unique antibodies with pre-specified characteristics.

This advanced technology allows us to express antibody fragments in bacteria or rapidly reformat into any given Ig format, such as full-size IgG of various isotypes, bispecifics, Fc mutants to modify effector functions, or chimeras with Fc regions from different species.

IPA supports chimeric antigen receptor (CAR) development by providing adaptable antibody discovery approaches and custom work plans designed to meet your requirements. Our diverse antibody discovery platforms, generate antibodies in different formats for CAR-T, while our precise high-throughput screening and characterization allows the inclusion of functional data early in the screening funnel. Multiple discovery methods yield broad spectrums of diverse antibodies, for further optimization with our platforms. Our human scFv library offers especially accelerates discovery timelines to complete your project with quality and efficiency.

It is critical to understand how to manage hybridoma cell lines and their potential to become unstable over time, and stop secreting antibody. With ImmunoProtect™, the DNA sequences of desirable antibodies are identified and subsequently used to produce your antibody recombinantly.

Custom assay development services fully tailored to your needs. IPA also provides assays developed in-house, available in our Products Catalog (e.g., Arthritis antibody mix (CAIA), PAD enzyme assay).